
Understanding Your Hereditary Cancer Risk Is the First Step Toward Protecting Your Future and the Future of Your Loved Ones.
Empower™ is a comprehensive germline genetic test developed by Natera to evaluate genetic alterations associated with hereditary cancer syndromes. Using a blood sample, the test assesses an individual’s inherited cancer risk, supporting the planning of early detection, screening, and risk management strategies.
Empower™ is used not only for hereditary cancer risk assessment but also to help identify inherited biomarkers that may influence treatment decisions in individuals diagnosed with cancer. In particular, alterations detected in BRCA1, BRCA2, and genes associated with Lynch syndrome may support the evaluation of targeted treatment options.
Identifying genetic variants associated with hereditary cancers enables risk assessment for both individuals and their family members. To provide a more comprehensive molecular profile, Empower™ can also be used alongside somatic genomic profiling tests such as FOCUS CGP veya Altera™ .
Cancer Types:
Breast, Ovarian, Endometrial (Uterine), Colorectal, Gastric, Prostate, Pancreatic, and Melanoma.
| Feature | Details |
|---|---|
Who Should Be Tested? |
|
Cancer Type | Hereditary Cancers |
| Sample Type | Blood (EDTA Tube) |
| Method | Next-Generation Sequencing (NGS) |
| Coverage | 81 Genes |
| Turnaround Time (TAT) | 2–3 Weeks |
* Genetic counseling is included as part of this test.
** BRCA1/2 MLPA analysis and the Lynch syndrome panel are included in this test.
*** The panel content can be customized based on clinical findings, family history, and genetic counseling. A detailed gene list is available upon request.
19 Mayıs Mah. Çoruh Sok. No:32/1 Fulya, Şişli / Istanbul
Monday - Friday 09:00 - 18:00 Saturday 09:00 - 14:00
The content provided on this site is intended for informational purposes only and is not a substitute for professional medical advice or diagnosis. Always seek the advice of a qualified healthcare provider for any medical evaluation, diagnosis, or treatment.
All rights reserved © 2026. Explicit Consent Statement | Last Updated: 27.04.2026 14:00 / mowaffak@hotmail.com
I acknowledge that I have read and understood the Privacy Notice provided by Nesiller Genetic Laboratories, acting as the data controller. The Privacy Notice clearly and comprehensively explains the identity of the data controller, the categories of personal data to be processed, the purposes of processing, the recipient groups to whom personal data may be transferred, the methods and legal grounds for data collection, and my rights as a data subject. I have also been informed that more detailed information is available in the Personal Data Retention and Destruction Policy and in the records maintained within the VERBIS system at the address indicated.
In addition to the matters described in the Privacy Notice, I freely give my explicit consent, with full awareness of the meaning, legal consequences, and potential future implications of this declaration, to the processing of my name, surname, email address, telephone number, company name, country, city, and address solely for the purposes of product and service promotions, gifts, discounts, new opportunities and special offers, announcements, advertisements, campaigns, personalized marketing activities, event invitations, and special occasion greetings, and for being contacted by email and SMS in accordance with the Law on the Regulation of Electronic Commerce and its applicable secondary legislation.
I further consent to the sharing of these personal data with companies providing SMS and email delivery services and marketing consultancy services with which Nesiller Genetic Laboratories has contractual relationships, solely for the purposes specified above.